Loading...
Prescription cannabidiol (CBD) use at approved dosages (as high as 25 mg/kg/day) can cause liver enzyme elevations. But does similar risk occur with lower doses typically used by consumers of various regulated and unregulated CBD-based products? Researchers randomized 200 healthy participants to receive 2.5 mg/kg oral CBD solution or placebo twice daily for 4 weeks and monitored liver tests weekly for 6 weeks total.
Key results were as follows:
Elevation of aspartate or alanine aminotransferase (AST or ALT) three times the upper limit of normal were significantly more common in the CBD group than in the placebo group (6% vs. 0%).
These elevations were first noted on day 21, peaked 1 to 2 days after stopping CBD, and normalized within 1 to 2 we…